Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part Study to Assess the Effects of Ritonavir on PRN1008 Pharmacokinetics, and the Effects of PRN1008 on QTc Interval Compared to Placebo and Moxifloxacin in Healthy Participants

Trial Profile

A Two-Part Study to Assess the Effects of Ritonavir on PRN1008 Pharmacokinetics, and the Effects of PRN1008 on QTc Interval Compared to Placebo and Moxifloxacin in Healthy Participants

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs PRN 1008 (Primary) ; Ritonavir
  • Indications Autoimmune disorders; Idiopathic thrombocytopenic purpura; Pemphigus vulgaris
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Principia Biopharma
  • Most Recent Events

    • 27 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top